Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, Pediatr Blood Cancer. juill, vol.51, issue.1, pp.71-76, 2000. ,
URL : https://hal.archives-ouvertes.fr/inserm-00255977
Incidence of Langerhans cell histiocytosis in children: a population-based study, Pediatr Blood Cancer. juill, vol.51, issue.1, pp.76-81, 2008. ,
Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders, Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc. déc, vol.7, issue.6, pp.607-621, 2004. ,
Nosology and Pathology of Langerhans Cell Histiocytosis, Hematol Oncol Clin North Am, vol.29, issue.5, pp.799-823, 2015. ,
Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders, Am J Surg Pathol. avr, vol.32, issue.4, pp.615-624, 2008. ,
Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules, Immunity. janv, vol.12, issue.1, pp.71-81, 2000. ,
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, issue.22, pp.2672-2681, 2016. ,
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years: Guidelines for Langerhans Cell Histiocytosis, Pediatr Blood Cancer. févr, vol.60, issue.2, pp.175-84, 2013. ,
Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society?Late Effects Study Group, Pediatr Blood Cancer. mai, vol.42, issue.5, pp.438-482, 2004. ,
Medical management of langerhans cell histiocytosis from diagnosis to treatment, Expert Opin Pharmacother. juin, vol.13, issue.9, pp.1309-1331, 2012. ,
Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study, J Child Neurol. mars, vol.15, issue.3, pp.150-156, 2000. ,
Central nervous system disease in Langerhans cell histiocytosis, J Pediatr. juin, vol.156, issue.6, p.1, 2010. ,
Neurohistiocytose langerhansienne. Presse Médicale, janv, vol.46, issue.1, pp.79-84, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01395227
Histiocytose langerhansienne de l'enfant. Presse Médicale, vol.46, pp.85-95, 2017. ,
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning, Bone Marrow Transplant, vol.36, issue.3, pp.215-225, 2005. ,
Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study, Blood. 17 sept, vol.126, issue.12, pp.1415-1438, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01231424
2?-chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society, Pediatr Blood Cancer. 15 déc, vol.53, issue.7, pp.1271-1277, 2009. ,
Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood. 16 sept, vol.116, issue.11, pp.1919-1942, 2010. ,
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other nonLangerhans cell histiocytoses, Blood. 27 sept, vol.120, issue.13, pp.2700-2703, 2012. ,
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy, J Clin Oncol. sept, vol.34, issue.25, pp.3023-3053, 2016. ,
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013. ,
Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis, JAMA Oncol. 1 sept, vol.1, issue.6, p.836, 2015. ,
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma, The Oncologist. juill, vol.22, issue.7, pp.823-856, 2017. ,
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Ann Oncol. juin, vol.24, issue.6, pp.1691-1698, 2013. ,
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study, Eur J Cancer Oxf Engl, vol.50, issue.3, pp.611-632, 1990. ,
Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature, Dermatol Res Pract, vol.2016, pp.1-6, 2016. ,
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, Lancet Oncol. avr, vol.15, issue.4, pp.436-480, 2014. ,
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, J Am Acad Dermatol. déc, vol.67, issue.6, pp.1265-72, 2012. ,
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy, BMC Cancer. 12 avr, vol.14, p.258, 2014. ,
Vemurafenib in pediatric patients with BRAFV 600E mutated high-grade gliomas: Vemurafenib in Pediatric High-Grade Gliomas, Pediatr Blood Cancer. juin, vol.61, issue.6, pp.1101-1104, 2014. ,
Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib, Pediatr Dermatol. mai, vol.34, issue.3, pp.337-378, 2017. ,
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent, J Transl Med, vol.12, 2017. ,
Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases, Childs Nerv Syst. avr, vol.34, issue.4, pp.605-615, 2018. ,
BRIM-P: A phase I, openlabel, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer, 2018. ,
, pediatric glioma: new therapeutic strategies, new toxicities, vol.12, pp.1397-405, 2016.
Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim–Chester disease, OncoTargets Ther. janv, vol.10, pp.521-527, 2017. ,
Pilomyxoid astrocytoma treated successfully with vemurafenib: Pilomyxoid Astrocytoma and Vemurafenib. Pediatr Blood Cancer, vol.61, pp.2099-100, 2014. ,
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol. mars, vol.15, issue.3, pp.323-355, 2014. ,
Vemurafenib-Induced Neutrophilic Panniculitis in a Child with a Brainstem Glioma, Pediatr Dermatol, vol.32, issue.1, pp.153-154, 2015. ,
Analysis of dermatologic events in vemurafenib-treated patients with melanoma, The Oncologist, vol.18, issue.3, pp.314-336, 2013. ,
Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1, Clin Cancer Res. 1 janv, vol.18, issue.1, pp.263-72, 2012. ,
RASopathic Skin Eruptions during Vemurafenib Therapy. Smalley K, éditeur, PLoS ONE. 14 mars, vol.8, issue.3, p.58721, 2013. ,
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, Br J Dermatol. avr, vol.170, issue.4, pp.997-1006, 2014. ,
Early-Onset Vemurafenib-Induced DRESS Syndrome, Dermatology, vol.232, issue.1, pp.126-134, 2016. ,
Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis, Br J Dermatol, vol.172, issue.5, pp.1454-1459, 2015. ,
,
, Ann Dermatol Venereol. mars, vol.141, issue.3, pp.215-223, 2014.
Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease, Br J Dermatol. déc, vol.171, issue.6, pp.1529-1561, 2014. ,
Ultraviolet A and Photosensitivity during Vemurafenib Therapy, N Engl J Med. 2 févr, vol.366, issue.5, pp.480-481, 2012. ,
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive, Eur J Dermatol EJD, vol.25, issue.5, pp.452-458, 2015. ,
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors, ACS Chem Biol. 20 mai, vol.11, issue.5, pp.1245-54, 2016. ,
Photoprotection in specific populations: Children and people of color, J Am Acad Dermatol. mars, vol.76, issue.3, pp.110-131, 2017. ,
Vázquez-veiga H. Vemurafenib-induced Neutrophilic Panniculitis: A New Case and Review of the Literature, Am J Dermatopathol, vol.38, issue.1, 2018. ,
Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature, J Eur Acad Dermatol Venereol. sept, vol.29, issue.9, pp.1797-806, 2015. ,
Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect, Case Rep Dermatol. 21 mars, vol.9, issue.1, pp.80-85, 2017. ,
Vemurafenib-induced panniculitis, Eur J Dermatol EJD. 1 avr, vol.23, issue.2, pp.258-60, 2013. ,
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature. 18 mars, vol.464, issue.7287, pp.431-436, 2010. ,
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors, N Engl J Med, vol.366, issue.3, pp.207-222, 2012. ,
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors, J Clin Oncol. 20 janv, vol.30, issue.3, pp.316-337, 2012. ,
, Classification HCL selon la classification de l'Histiocyte Society Cette classification se fait en fonction du nombre, du type d'organe ou de système atteint et par la présence d, ANNEXES Annexe, vol.1
, SS : un seul organe atteint sauf les poumons ou un RO MS RO-: plusieurs organes atteints sauf les poumons ou RO Lung+ : atteinte des poumons isolée ou avec d'autres organes sauf RO
atteinte d'au moins un RO avec possibilité d'une atteinte des autres organes sauf les poumons ND : déficit(s) neurologique(s) évolutif(s) irréversible(s) et caractéristiques IRM spécifiques ,
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years: Guidelines for Langerhans Cell Histiocytosis. Pediatr Blood Cancer. févr burns, never tans (pale white ,
, Type 2 usually burns, tans minimally (white; fair; blond or red hair; blue, green
, ? Type 3 sometimes mild burn, tans uniformly
, Type 6 never burns, never tans (deeply pigmented dark brown to darkest brown)
The validity and practicality of sun-reactive skin types i through vi, Archives of Dermatology, vol.124, issue.6, pp.869-871, 1988. ,